214 related articles for article (PubMed ID: 34608545)
1. Bioanalytical Challenges due to Prior Checkpoint Inhibitor Exposure: Interference and Mitigation in Drug Concentration and Immunogenicity Assays.
Dengler AF; Weiss R; Truong T; Irvin SC; Gadhia N; Hassanein M; Georgaros C; Taylor JA; Paccaly A; Sumner G; Andisik MD; Torri A; Partridge MA
AAPS J; 2021 Oct; 23(6):109. PubMed ID: 34608545
[TBL] [Abstract][Full Text] [Related]
2. Drug Target Interference in Immunogenicity Assays: Recommendations and Mitigation Strategies.
Zhong ZD; Clements-Egan A; Gorovits B; Maia M; Sumner G; Theobald V; Wu Y; Rajadhyaksha M
AAPS J; 2017 Nov; 19(6):1564-1575. PubMed ID: 29063411
[TBL] [Abstract][Full Text] [Related]
3. Comparing singlet and duplicate immunogenicity assay in human plasma for pembrolizumab using Gyrolab
Stanta JL; Craig H; Smith C; Chappell J
Bioanalysis; 2021 Jun; 13(11):891-900. PubMed ID: 33928794
[No Abstract] [Full Text] [Related]
4. Neutralizing Antibody Assay Development with High Drug and Target Tolerance to Support Clinical Development of an Anti-TFPI Therapeutic Monoclonal Antibody.
Xiang Y; Parng C; Olson K; Seletskaia E; Gorovits B; Jani D; Caiazzo T; Joyce A; Donley J
AAPS J; 2019 Mar; 21(3):46. PubMed ID: 30927117
[TBL] [Abstract][Full Text] [Related]
5. An innovative method for characterizing neutralizing antibodies against antibody-derived therapeutics.
Coddens A; Snoeck V; Bontinck L; Buyse MA; Pine SO
J Immunol Methods; 2020 Dec; 487():112896. PubMed ID: 33065122
[TBL] [Abstract][Full Text] [Related]
6. Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody.
Wang Y; Luong M; Guadiz C; Zhang M; Gorovits B
J Immunol Methods; 2019 Nov; 474():112642. PubMed ID: 31400410
[TBL] [Abstract][Full Text] [Related]
7. Development of an Enzyme-Linked Immune Sorbent Assay to Measure Nivolumab and Pembrolizumab Serum Concentrations.
Basak EA; Wijkhuijs AJM; Mathijssen RHJ; Koolen SLW; Schreurs MWJ
Ther Drug Monit; 2018 Oct; 40(5):596-601. PubMed ID: 29847460
[TBL] [Abstract][Full Text] [Related]
8. Interference in a Neutralizing Antibody Assay for Odronextamab, a CD20xCD3 Bispecific mAb, from Prior Rituximab Therapy and Possible Mitigation Strategy.
Irvin SC; D'Orvilliers A; Bloch N; Boccio K; Pennucci J; Brouwer-Visser J; Ullman E; Rajadhyaksha M; Hassanein M; Potocky T; Torri A; Hermann A; Partridge MA
AAPS J; 2022 Jun; 24(4):76. PubMed ID: 35725847
[TBL] [Abstract][Full Text] [Related]
9. A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays.
Zoghbi J; Xu Y; Grabert R; Theobald V; Richards S
J Immunol Methods; 2015 Nov; 426():62-9. PubMed ID: 26255760
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1).
Wu B; Sternheim N; Agarwal P; Suchomel J; Vadhavkar S; Bruno R; Ballinger M; Bernaards CA; Chan P; Ruppel J; Jin J; Girish S; Joshi A; Quarmby V
Clin Transl Sci; 2022 Jan; 15(1):130-140. PubMed ID: 34432389
[TBL] [Abstract][Full Text] [Related]
11. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
Naing A; Wong DJ; Infante JR; Korn WM; Aljumaily R; Papadopoulos KP; Autio KA; Pant S; Bauer TM; Drakaki A; Daver NG; Hung A; Ratti N; McCauley S; Van Vlasselaer P; Verma R; Ferry D; Oft M; Diab A; Garon EB; Tannir NM
Lancet Oncol; 2019 Nov; 20(11):1544-1555. PubMed ID: 31563517
[TBL] [Abstract][Full Text] [Related]
12. Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma.
Choi B; McBride A; Scott AJ
Am J Health Syst Pharm; 2019 Oct; 76(21):1749-1752. PubMed ID: 31612928
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of pembrolizumab in patients with advanced tumors.
van Vugt MJH; Stone JA; De Greef RHJMM; Snyder ES; Lipka L; Turner DC; Chain A; Lala M; Li M; Robey SH; Kondic AG; De Alwis D; Mayawala K; Jain L; Freshwater T
J Immunother Cancer; 2019 Aug; 7(1):212. PubMed ID: 31395089
[TBL] [Abstract][Full Text] [Related]
14. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
[TBL] [Abstract][Full Text] [Related]
15. Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid.
Pluim D; Ros W; van Bussel MTJ; Brandsma D; Beijnen JH; Schellens JHM
J Pharm Biomed Anal; 2019 Feb; 164():128-134. PubMed ID: 30368118
[TBL] [Abstract][Full Text] [Related]
16. Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma.
Sasson SC; Wilkins LE; Watson RA; Jolly C; Brain O; Klenerman P; Olsson-Brown A; Fairfax BP
Sci Rep; 2021 Sep; 11(1):19253. PubMed ID: 34584157
[TBL] [Abstract][Full Text] [Related]
17. Functional effects of immune complexes formed between pembrolizumab and patient-generated anti-drug antibodies.
Hock BD; McKenzie JL; Strother M; Goddard L; Butt L; Currie MJ
Cancer Immunol Immunother; 2020 Dec; 69(12):2453-2464. PubMed ID: 32556495
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of interleukin-5 induced false positive anti-drug antibody responses against mepolizumab through the use of a competitive blocking antibody.
Liao K; Meyer E; Lee TN; Loercher A; Sikkema D
J Immunol Methods; 2017 Feb; 441():15-23. PubMed ID: 27889561
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous adverse reactions to anti-PD-1 treatment-A systematic review.
Simonsen AB; Kaae J; Ellebaek E; Svane IM; Zachariae C
J Am Acad Dermatol; 2020 Nov; 83(5):1415-1424. PubMed ID: 32320766
[TBL] [Abstract][Full Text] [Related]
20. An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox.
Schneider AK; Vainshtein I; Roskos LK; Chavez C; Sun B; Liang M
J Immunol Methods; 2016 Aug; 435():68-76. PubMed ID: 27220271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
